doi:10.16150/j.1671-2870.2019.02.019

Abstract

CLC Number:

R715.2

References 31

[1]	Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxa-ban-Metabolism, Pharmacologic Properties and Drug Interactions[J]. Curr Drug Metab, 2017, 18(7):636-642.
[2]	Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361(12):1139-1151.
[3]	Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)[J]. Circulation, 2014, 130(2):138-146.
[4]	Chan YH, See LC, Tu HT, et al. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation[J]. J Am Heart Assoc, 2018, 7(8):e008150.
[5]	Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2013, 44(3):870-947.
[6]	Song Z, Wu H, Cao H, et al. Routine coagulation test abnormalities caused by rivaroxaban: A case report[J]. Medicine (Baltimore), 2018, 97(45):e13104.
[7]	Weitz JI, Eikelboom JW. Urgent Need to Measure Effects of Direct Oral Anticoagulants[J]. Circulation, 2016, 134(3):186-188.
[8]	Reiffel JA, Weitz JI, Reilly P, et al. NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank[J]. Am Heart J, 2016, 177:74-86.
[9]	Brown KS, Zahir H, Grosso MA, et al. Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal[J]. Crit Care, 2016, 20(1):273.
[10]	Bonar R, Favaloro EJ, Mohammed S, et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples[J]. Pathology, 2016, 48(1):60-71.
[11]	Testa S, Legnani C, Tripodi A, et al. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study[J]. J Thromb Haemost, 2016, 14(11):2194-2201.
[12]	Douxfils J, Tamigniau A, Chatelain B, et al. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays[J]. Thromb J, 2014, 12:24.
[13]	Henskens YMC, Gulpen AJW, van Oerle R, et al. Detecting clinically relevant rivaroxaban or dabigatran leve-ls by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation[J]. Thromb J, 2018, 16:3.
[14]	Samuelson BT, Cuker A. Measurement and reversal of the direct oral anticoagulants[J]. Blood Rev, 2017, 31(1):77-84.
[15]	Shimomura D, Nakagawa Y, Kondo H, et al. The Influe-nce of Assay Selection on Prothrombin Time Measured in Patients Treated With Rivaroxaban for Nonvalvular Atrial Fibrillation[J]. J Clin Lab Anal, 2016, 30(6):941-946.
[16]	Rathbun S, Tafur A, Grant R, et al. Comparison of metho-ds to determine rivaroxaban anti-factor Xa activity[J]. Thromb Res, 2015, 135(2):394-397.
[17]	Chan NC, Bhagirath V, Dale BJ, et al. Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants[J]. Expert Rev Cardiovasc Ther, 2015, 13(11):1213-1223.
[18]	Samuelson BT, Cuker A, Siegal DM, et al. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review[J]. Chest, 2017, 151(1):127-138.
[19]	Gosselin RC, Adcock DM. The laboratory's 2015 perspective on direct oral anticoagulant testing[J]. J Thromb Haemost, 2016, 14(5):886-893.
[20]	Vanden Daelen S, Peetermans M, Vanassche T, et al. Monitoring and reversal strategies for new oral anticoagulants[J]. Expert Rev Cardiovasc Ther, 2015, 13(1):95-103.
[21]	Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report[J]. Chest, 2018, 154(5):1121-1201.
[22]	Cuker A, Siegal DM, Crowther MA, et al. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants[J]. J Am Coll Cardiol, 2014, 64(11):1128-1139.
[23]	王哲, 谢秋芬, 向倩, 等. 直接口服抗凝药患者实验室检测的研究现状[J]. 中国临床药理学杂志, 2018, 34(10):1253-1256.
[24]	Colombini MP, Derogis PBMC, de Aranda VF, et al. Comparison of different laboratory tests in the evaluation of hemorrhagic risk of patients using rivaroxaban in the critical care setting: diagnostic accuracy study[J]. Thromb J, 2017, 15:21.
[25]	Bliden KP, Chaudhary R, Mohammed N, et al. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system[J]. J Thromb Thrombolysis, 2017, 43(4):437-445.
[26]	Seyve L, Richarme C, Polack B, et al. Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM)[J]. Int J Lab Hematol, 2018, 40(1):84-93.
[27]	Rohde G. Determination of rivaroxabana novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2008, 872(1-2):43-50.
[28]	Lindahl S, Dyrkorn R, Spigset O, et al. Quantification of Apixaban, Dabigatran, Edoxaban and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application[J]. Ther Drug Monit, 2018, 40(3):369-376.
[29]	Billoir P, Barbay V, Joly LM, et al. Anti-Xa Oral Anticoa-gulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator[J]. Ann Pharmacother, 2019, 53(4):341-347.
[30]	Gosselin RC, Francart SJ, Hawes EM, et al. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?[J]. Ann Pharmacother, 2015, 49(7):777-783.
[31]	Beyer J, Trujillo T, Fisher S, et al. Evaluation of a Hepa-rin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors[J]. Clin Appl Thromb Hemost, 2016, 22(5):423-428.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 31

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 425-430.
[2]	. [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 419-424.
[3]	HUANG Chen, JING Feng, YANG Zhitao, et al . Exploration and practice of construction of nursing management system in shelter hospital [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 286-290.
[4]	LIANG Jing, HUANG Chen, JIANG Yan, et al . Management strategy of nursing for prevention and control of COVID-19 in emergency infusion room [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 281-285.
[5]	ZHANG Hong, ZHU Mengmeng, et al . Safety nursing for eating in the elderly during the COVID-19 pandemic [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 277-280.
[6]	ZHOU Jianping, YANG Zhenhua, WANG Yichen, et al . Practice and thinking of the medical team of the elderly medical assistance center in the prevention and control of COVID-19 in Shanghai [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 265-269.
[7]	ZHA Qinghua, WANG Xiaoning, ZHANG Yin, et al . Exploration and practice of nucleic acid sampling outside hospital during the epidemic period of COVID-19 pandemic [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 229-233.
[8]	YU Ping, QIU Weiyu, WANG Xu, et al . Practice and exploration of drug security management in large shelter hospitals [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 221-224.
[9]	JIANG Yan, LIN Wei, HUANG Chen, et al . Exploration and practice of emergency supplies management mode in emergency department under COVID-19 pandemic [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 212-215.
[10]	TANG Jie, MA Longxin, CAO Qing, et al . Study on the construction of smart shelter hospital based on new generation information technology [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 196-204.
[11]	JIANG Yan, CHEN Ting, HUANG Chen, PAN Peiqian, JING Feng, et al . Construction and practice of emergency response capability training program for all staff in emergency medical ward under COVID-19：Emergency response strategy [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 189-195.
[12]	MENG Jun, JIN Peipei, CHEN Changqiang, CHEN Jiuming, FAN Zhenjia, CHEN Shikai, DAI Jing, et al . Emergency transformation experience of the laboratory department of a hospital designated for admission of patients with novel coronavirus infection in emergency conversion [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 184-188.
[13]	SHI Yingying, ZHONG Xu, LIU Jialin, HE Le, XIONG Shaoji, WENG Y, DING Chengwei, YANG Y, CHEN Weihon, QIU Liping, XIN Haiguang. Hospital infection prevention and control practices in anti-epidemic medical staff and workers during COVID-19 epidemic: investigation and countermeasures [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 178-183.
[14]	DING Ning, CHEN Shikai, MENG Jun, DAI Jing, JIN Peipei, et al . Correlation and influencing factors analysis of the cycle threshold value in detection of novel coronavirus nucleic acid(Omicron) and the negative conversion cycle in infected patients [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 169-173.
[15]	YANG Zhitao, CHEN Ying, JING Feng, XIE Zhihui, ZHANG Yibo, SHANG Hanbin, LIN Jingsheng, WU Wenjuan, GU Zhidong, BI Yufang, CHEN Erzhen. Practice and Exploration on the construction of medical affairs management system in large Fangcang hospitals [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 154-159.